CLINICAL TRIALS PROFILE FOR RUKOBIA
✉ Email this page to a colleague
All Clinical Trials for RUKOBIA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05220358 ↗ | Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study | Not yet recruiting | ViiV Healthcare | Phase 4 | 2022-03-01 | The RECOVER study is a self-controlled case series to evaluate whether the addition of Fostemsavir (Rukobia) to a stable HIV regimen in virologically suppressed patients living with HIV who never experience optimal CD4 T-cell count recovery can result in meaningful increases in different immunologic parameters such as CD4 T-cell count, CD4 T-cell percentage and CD4/CD8 ratio |
| NCT05220358 ↗ | Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study | Not yet recruiting | Orlando Immunology Center | Phase 4 | 2022-03-01 | The RECOVER study is a self-controlled case series to evaluate whether the addition of Fostemsavir (Rukobia) to a stable HIV regimen in virologically suppressed patients living with HIV who never experience optimal CD4 T-cell count recovery can result in meaningful increases in different immunologic parameters such as CD4 T-cell count, CD4 T-cell percentage and CD4/CD8 ratio |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RUKOBIA
Condition Name
Clinical Trial Progress for RUKOBIA
Clinical Trial Phase
Clinical Trial Sponsors for RUKOBIA
Sponsor Name
